About the Company - Alembic Pharmaceuticals Ltd
Alembic Pharmaceuticals Ltd. is a Public Limited Listed company incorporated on 16/06/2010 and has its registered office in the State of Gujarat, India. Company’s Corporate Identification Number(CIN) is L24230GJ2010PLC061123 and registration number is 061123. Currently Company is involved in the business activities of Manufacture of pharmaceuticals, medicinal chemical and botanical products. Company’s Total Operating Revenue is Rs. 5035.41 Cr. and Equity Capital is Rs. 39.31 Cr. for the Year ended 31/03/2022.
Management |
---|
Name | Position Held |
---|
Mr. Chirayu Amin | Chairman & CEO |
Mr. Pranav Amin | Managing Director |
Mr. Shaunak Amin | Managing Director |
Mr. R K Baheti | Director - Finance & CFO |
Mr. K G Ramanathan | Independent Director |
Mr. Pranav Parikh | Independent Director |
Mr. Paresh Saraiya | Independent Director |
Dr. Archana Hingorani | Independent Director |
Mr. Ashok Barat | Independent Director |
Mr. Jai Diwanji | Independent Director |
Alembic Pharmaceuticals Ltd. Share Price Update |
---|
Share Price | Value |
---|
Today | ₹725.50 |
Previous Day | ₹720.60 |
Basic Stock Data of Alembic Pharmaceuticals Ltd
Market Cap | 14,172 Cr. |
---|
Current Price | 721 |
---|
High / Low | 839/462 |
---|
Stock P/E | 26.6 |
---|
Book Value | 227 |
---|
Dividend Yield | 1.10 % |
---|
ROCE | 7.40 % |
---|
ROE | 7.20 % |
---|
Face Value | 2.00 |
---|
Alembic Pharmaceuticals Ltd Quarterly Results
Alembic Pharmaceuticals Ltd Quarterly Chart
Alembic Pharmaceuticals Ltd Profit & Loss
Month | Mar 2012 | Mar 2013 | Mar 2014 | Mar 2015 | Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | TTM |
---|
Sales | 1,465 | 1,520 | 1,863 | 2,056 | 3,166 | 3,105 | 3,131 | 3,935 | 4,606 | 5,393 | 5,306 | 5,653 | 5,997 |
Expenses | 1,246 | 1,268 | 1,506 | 1,653 | 2,159 | 2,490 | 2,488 | 3,061 | 3,383 | 3,913 | 4,432 | 4,970 | 5,151 |
Operating Profit | 219 | 252 | 358 | 403 | 1,007 | 615 | 643 | 874 | 1,223 | 1,480 | 874 | 682 | 845 |
OPM % | 15% | 17% | 19% | 20% | 32% | 20% | 21% | 22% | 27% | 27% | 16% | 12% | 14% |
Other Income | 13 | 4 | 4 | 4 | 7 | 2 | 7 | 9 | -39 | 87 | 56 | -2 | 23 |
Interest | 38 | 15 | 10 | 4 | 5 | 5 | 3 | 18 | 27 | 16 | 18 | 50 | 59 |
Depreciation | 34 | 35 | 40 | 44 | 72 | 83 | 105 | 115 | 157 | 183 | 287 | 275 | 274 |
Profit before tax | 161 | 206 | 311 | 359 | 936 | 529 | 541 | 749 | 1,000 | 1,368 | 625 | 355 | 535 |
Tax % | 19% | 20% | 24% | 21% | 23% | 23% | 22% | 21% | 20% | 19% | 17% | 4% | |
Net Profit | 130 | 165 | 236 | 283 | 720 | 403 | 413 | 583 | 801 | 1,146 | 521 | 342 | 532 |
EPS in Rs | 6.90 | 8.77 | 12.49 | 15.01 | 38.20 | 21.39 | 21.89 | 31.00 | 43.97 | 58.33 | 26.50 | 17.40 | 27.05 |
Dividend Payout % | 20% | 29% | 24% | 23% | 9% | 19% | 18% | 18% | 23% | 24% | 38% | 46% | |
Alembic Pharmaceuticals Ltd Profit & Loss Yearly Chart
Alembic Pharmaceuticals Ltd Growth
|
Compounded Sales Growth |
---|
10 Years:: | 14% |
5 Years:: | 13% |
3 Years:: | 7% |
TTM:: | 11% |
Alembic Pharmaceuticals Ltd Growth
|
Compounded Profit Growth |
---|
10 Years:: | 8% |
5 Years:: | -3% |
3 Years:: | -25% |
TTM:: | 104% |
Alembic Pharmaceuticals Ltd Growth
|
Stock Price CAGR |
---|
10 Years:: | 13% |
5 Years:: | 5% |
3 Years:: | -10% |
1 Year:: | 20% |
Alembic Pharmaceuticals Ltd Growth
|
Return on Equity |
---|
10 Years:: | 21% |
5 Years:: | 18% |
3 Years:: | 14% |
Last Year:: | 7% |
Alembic Pharmaceuticals Ltd Balance Sheet
Month | Mar 2012 | Mar 2013 | Mar 2014 | Mar 2015 | Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Sep 2023 |
---|
Equity Capital | 38 | 38 | 38 | 38 | 38 | 38 | 38 | 38 | 38 | 39 | 39 | 39 | 39 |
Reserves | 357 | 465 | 638 | 847 | 1,560 | 1,865 | 2,182 | 2,681 | 3,182 | 5,028 | 5,198 | 4,331 | 4,431 |
Borrowings | 353 | 187 | 109 | 264 | 114 | 89 | 708 | 1,128 | 1,747 | 584 | 717 | 722 | 869 |
Other Liabilities | 304 | 358 | 432 | 493 | 718 | 698 | 1,013 | 931 | 1,022 | 1,058 | 1,167 | 1,090 | 1,116 |
Total Liabilities | 1,052 | 1,048 | 1,217 | 1,641 | 2,429 | 2,689 | 3,941 | 4,778 | 5,989 | 6,709 | 7,122 | 6,183 | 6,455 |
Fixed Assets | 268 | 344 | 397 | 547 | 708 | 799 | 993 | 1,158 | 1,552 | 1,788 | 1,798 | 2,398 | 2,603 |
CWIP | 58 | 32 | 21 | 83 | 93 | 396 | 1,010 | 1,551 | 1,846 | 2,183 | 2,304 | 601 | 478 |
Investments | 3 | 3 | 3 | 2 | 87 | 50 | 42 | 49 | 18 | 236 | 118 | 96 | 98 |
Other Assets | 723 | 668 | 796 | 1,009 | 1,541 | 1,444 | 1,896 | 2,019 | 2,573 | 2,502 | 2,902 | 3,087 | 3,277 |
Total Assets | 1,052 | 1,048 | 1,217 | 1,641 | 2,429 | 2,689 | 3,941 | 4,778 | 5,989 | 6,709 | 7,122 | 6,183 | 6,455 |
Alembic Pharmaceuticals Ltd Reserves and Borrowings Chart
Alembic Pharmaceuticals Ltd Cash Flow
Month | Mar 2012 | Mar 2013 | Mar 2014 | Mar 2015 | Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 |
---|
Cash from Operating Activity | 142 | 265 | 240 | 172 | 948 | 329 | 312 | 812 | 449 | 1,463 | 552 | 724 |
Cash from Investing Activity | -56 | -67 | -81 | -256 | -307 | -486 | -884 | -756 | -731 | -840 | -372 | -448 |
Cash from Financing Activity | -45 | -229 | -151 | 87 | -224 | -129 | 503 | 59 | 155 | -597 | -217 | -262 |
Net Cash Flow | 41 | -31 | 8 | 3 | 417 | -286 | -69 | 115 | -127 | 26 | -37 | 14 |
|
Alembic Pharmaceuticals Ltd Financial Efficiency Indicators
Month | Mar 2012 | Mar 2013 | Mar 2014 | Mar 2015 | Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 |
---|
Debtor Days | 50 | 56 | 54 | 64 | 40 | 40 | 61 | 45 | 69 | 24 | 56 | 68 |
Inventory Days | 133 | 143 | 159 | 196 | 266 | 269 | 302 | 356 | 417 | 431 | 406 | 315 |
Days Payable | 108 | 129 | 148 | 166 | 264 | 213 | 313 | 237 | 220 | 194 | 178 | 145 |
Cash Conversion Cycle | 75 | 70 | 65 | 94 | 42 | 96 | 51 | 164 | 266 | 261 | 283 | 237 |
Working Capital Days | 61 | 59 | 50 | 71 | 49 | 72 | 93 | 64 | 118 | 94 | 118 | 119 |
ROCE % | 29% | 31% | 44% | 38% | 66% | 29% | 22% | 23% | 24% | 26% | 11% | 7% |
Alembic Pharmaceuticals Ltd Financial Efficiency Indicators Chart
No valid data available for the Shareholding
Alembic Pharmaceuticals Ltd Shareholding Pattern Chart
No. of Alembic Pharmaceuticals Ltd Shareholders
Alembic Pharmaceuticals Ltd Mutual Fund Holdings
Fund Name | No of Shares | AUM (%) | Amount Invested (Cr) |
---|
DSP Mid Cap Fund | 4766071 | 2.46 | 370.18 |
Kotak Small Cap Fund - Regular Plan | 3865125 | 2.44 | 300.2 |
DSP Tax Saver Fund | 1727123 | 1.13 | 134.15 |
DSP Healthcare Fund | 1233068 | 5.82 | 95.77 |
DSP Top 100 Equity Fund | 544088 | 1.42 | 42.26 |
Aditya Birla Sun Life Small Cap Fund | 450752 | 0.78 | 35.01 |
DSP Small Cap Fund | 438128 | 0.28 | 34.03 |
ICICI Prudential Pharma Healthcare & Diagnostics (P.H.D) Fund | 296505 | 0.73 | 23.03 |
Aditya Birla Sun Life Pharma & Healthcare Fund | 161138 | 2.4 | 12.52 |
UTI Healthcare Fund | 120000 | 1.2 | 9.32 |
Alembic Pharmaceuticals Ltd ROCE Trend
Alembic Pharmaceuticals Ltd EPS Trend
Alembic Pharmaceuticals Ltd Key Financial Ratios
Month | Mar 23 | Mar 22 | Mar 21 | Mar 20 | Mar 19 |
---|
FaceValue | 2.00 | 2.00 | 2.00 | 2.00 | 2.00 |
Basic EPS (Rs.) | 17.40 | 26.50 | 60.81 | 43.97 | 31.00 |
Diluted EPS (Rs.) | 17.40 | 26.50 | 60.81 | 43.97 | 31.00 |
Cash EPS (Rs.) | 32.99 | 40.83 | 66.05 | 50.82 | 37.55 |
Book Value[Excl.RevalReserv]/Share (Rs.) | 222.36 | 266.47 | 257.80 | 169.25 | 144.19 |
Book Value[Incl.RevalReserv]/Share (Rs.) | 222.36 | 266.47 | 257.80 | 169.25 | 144.19 |
Revenue From Operations / Share (Rs.) | 287.59 | 269.95 | 274.39 | 244.34 | 208.74 |
PBDIT / Share (Rs.) | 36.18 | 47.04 | 79.75 | 65.14 | 46.84 |
PBIT / Share (Rs.) | 22.17 | 32.45 | 70.42 | 56.80 | 40.73 |
PBT / Share (Rs.) | 19.61 | 31.55 | 69.60 | 53.04 | 39.75 |
Net Profit / Share (Rs.) | 18.97 | 26.23 | 56.72 | 42.47 | 31.44 |
NP After MI And SOA / Share (Rs.) | 17.40 | 26.50 | 59.94 | 43.97 | 31.00 |
PBDIT Margin (%) | 12.58 | 17.42 | 29.06 | 26.66 | 22.44 |
PBIT Margin (%) | 7.70 | 12.02 | 25.66 | 23.24 | 19.51 |
PBT Margin (%) | 6.82 | 11.68 | 25.36 | 21.70 | 19.04 |
Net Profit Margin (%) | 6.59 | 9.71 | 20.67 | 17.38 | 15.06 |
NP After MI And SOA Margin (%) | 6.05 | 9.81 | 21.84 | 17.99 | 14.85 |
Return on Networth / Equity (%) | 7.82 | 9.94 | 22.97 | 25.74 | 21.49 |
Return on Capital Employeed (%) | 9.58 | 11.79 | 25.49 | 25.26 | 23.34 |
Return On Assets (%) | 5.53 | 7.31 | 17.56 | 13.83 | 12.23 |
Long Term Debt / Equity (X) | 0.00 | 0.00 | 0.03 | 0.27 | 0.18 |
Total Debt / Equity (X) | 0.14 | 0.12 | 0.03 | 0.54 | 0.34 |
Asset Turnover Ratio (%) | 0.77 | 0.73 | 0.79 | 0.77 | 0.86 |
Current Ratio (X) | 1.78 | 1.67 | 2.01 | 1.41 | 1.31 |
Quick Ratio (X) | 0.87 | 0.72 | 0.85 | 0.72 | 0.66 |
Inventory Turnover Ratio (X) | 0.86 | 0.78 | 0.93 | 0.95 | 1.05 |
Dividend Payout Ratio (NP) (%) | 57.47 | 52.82 | 0.00 | 39.32 | 15.55 |
Dividend Payout Ratio (CP) (%) | 31.83 | 34.06 | 0.00 | 33.05 | 12.99 |
Earning Retention Ratio (%) | 42.53 | 47.18 | 0.00 | 60.68 | 84.45 |
Cash Earning Retention Ratio (%) | 68.17 | 65.94 | 0.00 | 66.95 | 87.01 |
Interest Coverage Ratio (%) | 14.17 | 52.15 | 97.85 | 45.21 | 47.96 |
Interest Coverage Ratio (Post Tax) (%) | 8.43 | 30.08 | 70.59 | 32.09 | 33.19 |
Enterprise Value (Cr.) | 10301.50 | 15131.79 | 19003.45 | 11697.08 | 10722.89 |
EV / Net Operating Revenue (X) | 1.82 | 2.85 | 3.52 | 2.54 | 2.73 |
EV / EBITDA (X) | 14.49 | 16.37 | 12.12 | 9.53 | 12.14 |
MarketCap / Net Operating Revenue (X) | 1.72 | 2.75 | 3.52 | 2.18 | 2.54 |
Retention Ratios (%) | 42.52 | 47.17 | 0.00 | 60.67 | 84.44 |
Price / BV (X) | 2.23 | 2.78 | 3.70 | 3.12 | 3.68 |
Price / Net Operating Revenue (X) | 1.72 | 2.75 | 3.52 | 2.18 | 2.54 |
EarningsYield | 0.03 | 0.03 | 0.06 | 0.08 | 0.05 |
Alembic Pharmaceuticals Ltd Profitability Ratios (%)
Alembic Pharmaceuticals Ltd Liquidity Ratios
Alembic Pharmaceuticals Ltd Liquidity Ratios (%)
Alembic Pharmaceuticals Ltd Interest Coverage Ratios (%)
Alembic Pharmaceuticals Ltd Valuation Ratios
Strength and Weakness of Alembic Pharmaceuticals Ltd Stock
Strength | Weakness |
---|
The company has shown consistent growth in sales and profit over the years. | The stock has a low average ROCE, which may not be favorable. The stock has a high average Working Capital Days, which may not be favorable. The stock has a high average Cash Conversion Cycle, which may not be favorable. The company has higher borrowings compared to reserves, which may suggest financial risk. |